IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 3333 01
E-Mail: investor@medigene.com

FRüHERE MELDUNGEN

06.05.2022 - 18:30 | Medigene AG
06.05.2022 - 18:30 | Medigene AG
06.05.2022 - 18:25 | Medigene AG
06.05.2022 - 18:25 | Medigene AG
04.05.2022 - 07:30 | Medigene AG
pta20220512084
Public disclosure of inside information according to article 17 MAR

Medigene AG: Dr Selwyn Ho appointed new CEO of Medigene


Planegg/Martinsried (pta084/12.05.2022/18:35) - The Supervisory Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, today appointed Dr Selwyn Ho as a member of the Executive Management Board and as new Chief Executive Officer (CEO) of Medigene with effect of 25 July 2022. He accepted the appointments.

As a consequence, Prof. Dolores Schendel will step down as Chief Executive Officer at the end of 24 July 2022 and fully focus on her responsibilities as Chief Scientific Officer (CSO) and Head of Research and Development at Medigene.

(end)
Emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg/Martinsried
Germany
Contact Person: Medigene PR/IR
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com
Website: www.medigene.com
Stock Exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00 (share)
|
|
98.796 Abonnenten
|
204.854 Meldungen
|
84.703 Pressefotos

BUSINESS

02.12.2022 - 11:30 | pressetext.redaktion
02.12.2022 - 10:00 | Agentur für Gesundheit & Wellness
02.12.2022 - 06:15 | pressetext.redaktion
01.12.2022 - 13:59 | pressetext.redaktion
01.12.2022 - 10:55 | G DATA CyberDefense
Top